These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Hinotsu S; Akaza H; Isaka S; Kanetake H; Kubota Y; Kuroda M; Shinohara N; Shinka T; Tachibana M; Naito S; Hirao Y; Urology; 2006 Mar; 67(3):545-9. PubMed ID: 16527576 [TBL] [Abstract][Full Text] [Related]
15. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence]. Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813 [TBL] [Abstract][Full Text] [Related]
16. [Prophylactic effect of etretinate on the recurrence of superficial bladder tumors--results of a randomized control study]. Yoshida O; Miyakawa M; Watanabe H; Mishina T; Okajima E; Hirao Y; Matushima M; Nihira H; Nakatsu H Hinyokika Kiyo; 1986 Sep; 32(9):1349-58. PubMed ID: 3544744 [TBL] [Abstract][Full Text] [Related]
18. [Our experience with mitomycin C in the prophylaxis of superficial bladder tumors; retrospective study]. Moyano Calvo JL; Herrero Torres L; Melón Rey FJ; Rabadán Ruiz M; Pereira Sanz I Arch Esp Urol; 1994 Oct; 47(8):750-4. PubMed ID: 7818293 [TBL] [Abstract][Full Text] [Related]
19. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Jain A; Phillips RM; Scally AJ; Lenaz G; Beer M; Puri R Urology; 2009 May; 73(5):1083-6. PubMed ID: 19232688 [TBL] [Abstract][Full Text] [Related]
20. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer. Li M; Song T; Yin ZF; Na YQ Chin Med J (Engl); 2007 Mar; 120(6):469-73. PubMed ID: 17439739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]